Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Staessen

Showing results (471-480 of 565) with videos related to

Pageof 57
Sort By:
European Journal of Heart Failure|January 18, 2020
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trialPierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni, et al.
Blood Pressure|July 15, 2025
Evaluation of race-free eGFR equations in individuals of different ethnicityDe-Wei An, Gontse G Mokwatsi, Dong-Yan Zhang, et al.
Cardiovascular Research|March 20, 2026
The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in HypertensionMarek Rajzer, Wiktoria Wojciechowska, Andrzej Januszewicz, et al.
European Journal of Heart Failure|November 29, 2021
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trialSusana Ravassa, Begoña López, João Pedro Ferreira, et al.
Blood Pressure|April 19, 2011
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trialAugustine N Odili, Tom Richart, Lutgarde Thijs, et al.
Journal of Hypertension|September 2, 2022
Renal denervation in the antihypertensive arsenal - knowns and known unknownsFranz H Messerli, Chirag Bavishi, Jana Brguljan, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 6, 2024
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trialFang-Fei Wei, Pierpaolo Pellicori, João Pedro Ferreira, et al.
ESC Heart Failure|August 11, 2024
Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failureFang-Fei Wei, Beatrice Mariottoni, De-Wei An, et al.
European Journal of Heart Failure|June 15, 2022
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trialMasatake Kobayashi, Nicolas Girerd, João Pedro Ferreira, et al.
BMC Genetics|October 3, 2015
Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish populationWen-Yi Yang, Thibault Petit, Lutgarde Thijs, et al.
Pageof 57

Showing results (471-480 of 565) with videos related to

Sort By:
Pageof 57
European Journal of Heart Failure|January 18, 2020
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trialPierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni, et al.
Blood Pressure|July 15, 2025
Evaluation of race-free eGFR equations in individuals of different ethnicityDe-Wei An, Gontse G Mokwatsi, Dong-Yan Zhang, et al.
Cardiovascular Research|March 20, 2026
The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in HypertensionMarek Rajzer, Wiktoria Wojciechowska, Andrzej Januszewicz, et al.
European Journal of Heart Failure|November 29, 2021
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trialSusana Ravassa, Begoña López, João Pedro Ferreira, et al.
Blood Pressure|April 19, 2011
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trialAugustine N Odili, Tom Richart, Lutgarde Thijs, et al.
Journal of Hypertension|September 2, 2022
Renal denervation in the antihypertensive arsenal - knowns and known unknownsFranz H Messerli, Chirag Bavishi, Jana Brguljan, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 6, 2024
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trialFang-Fei Wei, Pierpaolo Pellicori, João Pedro Ferreira, et al.
ESC Heart Failure|August 11, 2024
Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failureFang-Fei Wei, Beatrice Mariottoni, De-Wei An, et al.
European Journal of Heart Failure|June 15, 2022
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trialMasatake Kobayashi, Nicolas Girerd, João Pedro Ferreira, et al.
BMC Genetics|October 3, 2015
Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish populationWen-Yi Yang, Thibault Petit, Lutgarde Thijs, et al.
Pageof 57